Design Therapeutics
DSGN
92 hedge funds and large institutions have $116M invested in Design Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 35 increasing their positions, 34 reducing their positions, and 11 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 34
0.12% more ownership
Funds ownership: 60.71% → 60.83% (+0.12%)
6% less funds holding
Funds holding: 98 → 92 (-6)
13% less capital invested
Capital invested by funds: $133M → $116M (-$16.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$609K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$493K |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$470K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$374K |
| 5 |
AC
Almitas Capital
Santa Monica,
California
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$546K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$459K |
| 3 |
Millennium Management
New York
|
-$340K |
| 4 |
BlackRock
New York
|
-$315K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$184K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Simplex Trading
Chicago,
Illinois
| – | -$1K | -263 | Closed |
|
|
GI
102
GAMMA Investing
Foster City,
California
| – | -$880 | -228 | Closed |
|
|
PS
103
Principal Securities
Des Moines,
Iowa
| – | -$457 | -74 | Closed |
|
DSGN Hedge Fund Activity: Q2 2025 in Review
92 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2025, worth a combined $116M — down 13% from $133M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DSGN and 5 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 35 added.
The largest buyer was Driehaus Capital Management, adding an estimated $609K. The largest seller was Wellington Management Group, exiting entirely with an estimated $546K sold.
- 92 institutional investors held Design Therapeutics (DSGN) as of Q2 2025, down from 98 in Q1 2025.
- Funds reported $116M of Design Therapeutics stock for Q2 2025, down 13% quarter-over-quarter.
- 5 funds opened new Design Therapeutics positions in Q2 2025 and 11 closed out, a net change of -6 holders.
- The largest Design Therapeutics buyer in Q2 2025 was Driehaus Capital Management, an estimated $609K added.
- The largest Design Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $546K sold.
Based on aggregated 13F filings for Q2 2025.